Literature DB >> 8141577

Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group.

G Gerna1, F Baldanti, A Sarasini, M Furione, E Percivalle, M G Revello, D Zipeto, D Zella.   

Abstract

The aim of this study was to investigate peripheral blood polymorphonuclear leukocytes and, whenever possible, aqueous humor from 65 AIDS patients with ophthalmoscopically diagnosed human cytomegalovirus (HCMV) retinitis to determine (i) whether patients consistently carry viral DNA and (ii) to what extent foscarnet induction treatment decreases viral DNA levels. HCMV DNA was quantified by PCR using densitometric analysis of hybridization products obtained from external standards and a standard curve from which the number of genome equivalents of test samples, normalized by using an internal amplification control, was interpolated. Results showed that 56 of 65 patients (86.1%) were positive for HCMV DNA prior to induction treatment. Of 41 of the 56 patients (73.2%) whose blood had become DNA negative after induction, only 5 had a high viral load (> 5,000 genome equivalents per 2 x 10(5) polymorphonuclear leukocytes) prior to induction, whereas as many as 13 of the 15 (26.8%) patients remaining DNA positive after induction had a high viral load prior to induction. Finally, of the nine patients (13.8%) with DNA-negative blood prior to induction treatment, three were shifted to foscarnet from ganciclovir, while six were erroneously enrolled in the study. Pre- and postinduction aqueous humor samples were obtained from 12 patients; all of these were DNA positive prior to induction, whereas after induction, 4 became negative, 6 showed a marked decrease in viral DNA, and 2 had nearly stable low DNA levels. In conclusion, PCR is a valuable tool for etiologic diagnosis and monitoring of HCMV retinitis treatment in AIDS patients. HCMV DNA is consistently present in the blood and aqueous humor of all patients with HCMV retinitis. Foscarnet induction treatment is highly effective in suppressing or reducing DNA levels in both blood leukocytes and aqueous humor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8141577      PMCID: PMC284393          DOI: 10.1128/AAC.38.1.38

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Treatment of cytomegalovirus retinopathy with ganciclovir.

Authors:  G N Holland; Y Sidikaro; A E Kreiger; D Hardy; M J Sakamoto; L M Frenkel; D J Winston; M S Gottlieb; Y J Bryson; R E Champlin
Journal:  Ophthalmology       Date:  1987-07       Impact factor: 12.079

2.  Treatment of cytomegalovirus retinitis with ganciclovir.

Authors:  D A Jabs; C Newman; S De Bustros; B F Polk
Journal:  Ophthalmology       Date:  1987-07       Impact factor: 12.079

3.  Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine.

Authors:  A G Palestine; G Stevens; H C Lane; H Masur; L S Fujikawa; R B Nussenblatt; A H Rook; J Manischewitz; B Baird; M Megill
Journal:  Am J Ophthalmol       Date:  1986-01-15       Impact factor: 5.258

4.  Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients.

Authors:  W C Buhles; B J Mastre; A J Tinker; V Strand; S H Koretz
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

5.  Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.

Authors:  M A Jacobson; J J O'Donnell; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

6.  Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome.

Authors:  P Lehoang; B Girard; M Robinet; P Marcel; L Zazoun; S Matheron; W Rozenbaum; C Katlama; I Morer; J O Lernestedt
Journal:  Ophthalmology       Date:  1989-06       Impact factor: 12.079

7.  Quantification of human cytomegalovirus DNA in peripheral blood polymorphonuclear leukocytes of immunocompromised patients by the polymerase chain reaction.

Authors:  D Zipeto; F Baldanti; D Zella; M Furione; A Cavicchini; G Milanesi; G Gerna
Journal:  J Virol Methods       Date:  1993-09       Impact factor: 2.014

8.  Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy.

Authors:  M A Jacobson; J J O'Donnell; D Porteous; H R Brodie; D Feigal; J Mills
Journal:  Q J Med       Date:  1988-06

9.  Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).

Authors:  S L Walmsley; E Chew; S E Read; H Vellend; I Salit; A Rachlis; M M Fanning
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

10.  Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.

Authors:  J Sjövall; S Bergdahl; G Movin; S Ogenstad; M Saarimäki
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

View more
  22 in total

1.  A highly sensitive assay for detection and quantitation of human cytomegalovirus DNA in serum and plasma by PCR and electrochemiluminescence.

Authors:  R Boom; C Sol; J Weel; Y Gerrits; M de Boer; P Wertheim-van Dillen
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

2.  Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virus-infected subjects.

Authors:  G Boivin; J Handfield; E Toma; G Murray; R Lalonde; V J Tevere; R Sun; M G Bergeron
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

3.  Quantitation of cytomegalovirus (CMV) DNA in leukocytes of human immunodeficiency virus-infected subjects with and without CMV disease by using PCR and the SHARP Signal Detection System.

Authors:  G Boivin; J Handfield; G Murray; E Toma; R Lalonde; J G Lazar; M G Bergeron
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

Review 4.  New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients.

Authors:  I G Sia; R Patel
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 5.  Analysis of ocular fluids for local antibody production in uveitis.

Authors:  J H de Boer; L Luyendijk; A Rothova; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

6.  Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients.

Authors:  G Gerna; F Baldanti; D Lilleri; M Parea; E Alessandrino; A Pagani; F Locatelli; J Middeldorp; M G Revello
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

7.  Utility of major leukocyte subpopulations for monitoring secondary cytomegalovirus infections in renal-allograft recipients by PCR.

Authors:  P Schäfer; W Tenschert; L Cremaschi; K Gutensohn; R Laufs
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

Review 8.  Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.

Authors:  Raymund R Razonable; Randall T Hayden
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  Quantitative PCR for human herpesviruses 6 and 7.

Authors:  P Secchiero; D Zella; R W Crowley; R C Gallo; P Lusso
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

10.  Identification of human cytomegalovirus strain with immediate-early (IE) antigen-specific monoclonal antibody is prevented by point mutation in IE gene.

Authors:  D Zipeto; A Sarasini; F Rossi; F Baldanti; M G Revello; G Milanesi; G Gerna
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.